Syschem (India) Limited (531173) Fair Value & Analysis
Healthcare · IN · Market cap ₹126M
Fair value as of: Jul 4, 2026
From 14 valuation models · updated today
Share price −14.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹40.48 – ₹59.89 · fair‑value band ₹5.21 – ₹8.68 · the ₹40.64 price screens above the ₹6.95 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Syschem (India) Limited (531173) currently trades at ₹40.64, while our model-based Fair Value estimate is ₹6.95 — implying the stock looks roughly 82.9% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Syschem (India) Limited generated revenue of ₹717M at a net margin of -4.9%. Revenue declined 32.8% year over year. Net debt stands at ₹3.5M. The stock trades on a trailing P/E of 60.8. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Syschem (India) Limited manufactures and sells active pharmaceuticals ingredients (APIs), intermediates, bulk drugs, and specialty chemicals in India. Its APIs/intermediates include amoxycillin trihydrate, ampicillin trihydrate, cloxacillin sodium, dicloxacillin sodium, flucloxacillin sodium, cephalexin, cefixime, and cefadroxil. The company also offers generic products in tablet, softgel/capsule, injection, syrup/suspension, and herbal and personal care forms. In addition, it engages in the distillation of specialty solvents, such as DMF, acetonitrile, ethyl acetate, and THF; and contract manufacturing business. The company was incorporated in 1993 and is based in Chandigarh, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Syschem (India) Limited reported revenue of ₹6.5B in FY2026 versus ₹656M in FY2022, a compound +77.7%/yr. Reported net income was ₹109M in FY2026.
Is 531173 fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Syncom Formulations (India) Limited 524470 | ₹14.23 | ₹10.20 | -28% |
| Makers Laboratories Limited 506919 | ₹151.45 | ₹105.20 | -31% |
| Unjha Formulations Limited 531762 | ₹18.55 | ₹34.60 | +87% |
| Colinz Laboratories Limited 531210 | ₹77.55 | ₹14.60 | -81% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| UnitedHealth Group UNH | 7,169 MXN | 5,226 MXN | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Syschem (India) Limited (531173) undervalued?
What is the fair value of 531173?
What is the quality score of 531173?
What is the revenue of Syschem (India) Limited (531173)?
What is the net profit margin of 531173?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.